Appointment dossier — Neuroblastoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Neuroblastoma
- Genistein — Review evidence · 1 positive · PMID 42133114
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07549321 · Phase 2 / Phase 3 — A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients (United States)
- NCT06071897 · Phase 3 — Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma (Russia)
- NCT05489887 · Phase 2 — Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (United States)
- NCT06013618 · Phase 2 — Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma (China)
- NCT06540963 · Phase 2 — Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma (United States)
- NCT02559778 · Phase 2 — Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (United States)
- NCT05135975 · Phase 2 — A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors (United States)
- NCT05701306 · Phase 1 / Phase 2 — APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors (China)
- NCT06395103 · Phase 1 / Phase 2 — Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) (United States)
- NCT05754684 · Phase 2 — Quadruple Immunotherapy for Neuroblastoma (Hong Kong)
- NCT06721689 · Phase 1 / Phase 2 — PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors (United States)
- NCT06528496 · Phase 2 — N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (United States)
- NCT06803875 · Phase 1 / Phase 2 — Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma (United States)
- NCT06485947 · Phase 1 — Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma (Netherlands)
- NCT06674265 · Phase 1 — Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma (Iran)
- NCT04897321 · Phase 1 — B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (United States)
- NCT06479811 · Phase 1 — [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (United States)
- NCT06995872 · Phase 1 — Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma (United States)
Most-relevant first: trials that name Neuroblastoma, then broader trials you may still qualify for. 109 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT07549321), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?